Education
About Us
Working with TipRanks
Follow Us
Dianthus Therapeutics (DNTH)
NASDAQ:DNTH
DNTH Stock Chart & Stats
$43.15
$0.37(1.44%)
At close: 4:00 PM EST
$43.15
$0.37(1.44%)
Day’s Range― - ―
52-Week Range$13.37 - $45.46
Previous CloseN/A
Volume29.07K
Average Volume (3M)1.00M
Market Cap
$1.85B
Enterprise Value$411.31M
Total Cash (Recent Filing)$402.61M
Total Debt (Recent Filing)$1.28M
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Mar 19, 2026EPS Estimate
-1.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.97
Shares Outstanding42,876,015
10 Day Avg. Volume588,847
30 Day Avg. Volume1,003,841
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.06
Price to Sales (P/S)116.48
P/FCF Ratio-9.28
Enterprise Value/Market Cap0.22
Enterprise Value/Revenue133.63
Enterprise Value/Gross Profit133.63
Enterprise Value/Ebitda-3.01
Forecast
1Y Price Target
$58.71Price Target Upside36.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial HealthDianthus Therapeutics has approximately $525 million in adjusted cash, cash equivalents, and investments, which are expected to fund operations into 2028.
Pipeline ExpansionDianthus announced an agreement to acquire global rights for DNTH212, a first-in-class bifunctional antibody, believed to drive superior efficacy across numerous potential autoimmune indications.
Research And DevelopmentPhase 3 gMG study expected to start in 2026, following positive Phase 2 MaGic topline data for the treatment of myasthenia gravis.
Bears Say
Clinical DevelopmentThere are questions on dose selection in Phase III for gMG, particularly the proposed 300 mg Q4W arm alongside the Q2W option.
Earnings PerformanceFor 3Q25, Dianthus reported a net loss of $0.97 per share, which was higher than the consensus estimate of a $0.87 loss per share.
Market SentimentShort interest for Dianthus Therapeutics' stock is relatively high at 12.3% of the float, indicating potential skepticism or bearish sentiment from investors.
Dianthus Therapeutics News
DNTH FAQ
What was Dianthus Therapeutics’s price range in the past 12 months?
Dianthus Therapeutics lowest stock price was $13.37 and its highest was $45.45 in the past 12 months.
What is Dianthus Therapeutics’s market cap?
Dianthus Therapeutics’s market cap is $1.85B.
When is Dianthus Therapeutics’s upcoming earnings report date?
Dianthus Therapeutics’s upcoming earnings report date is Mar 19, 2026 which is in 82 days.
How were Dianthus Therapeutics’s earnings last quarter?
Dianthus Therapeutics released its earnings results on Nov 05, 2025. The company reported -$0.97 earnings per share for the quarter, missing the consensus estimate of -$0.867 by -$0.103.
Is Dianthus Therapeutics overvalued?
According to Wall Street analysts Dianthus Therapeutics’s price is currently Undervalued.
Does Dianthus Therapeutics pay dividends?
Dianthus Therapeutics does not currently pay dividends.
What is Dianthus Therapeutics’s EPS estimate?
Dianthus Therapeutics’s EPS estimate is -1.07.
How many shares outstanding does Dianthus Therapeutics have?
Dianthus Therapeutics has 42,876,015 shares outstanding.
What happened to Dianthus Therapeutics’s price movement after its last earnings report?
Dianthus Therapeutics reported an EPS of -$0.97 in its last earnings report, missing expectations of -$0.867. Following the earnings report the stock price went up 8.005%.
Which hedge fund is a major shareholder of Dianthus Therapeutics?
Currently, no hedge funds are holding shares in DNTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dianthus Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$58.71 (36.06% Upside)
$58.71 (36.06% Upside)
Hedge Fund Trend
Increased
By 251.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.18%
12-Months-Change
Fundamentals
Return on Equity
-28.57%
Trailing 12-Months
Asset Growth
-11.62%
Trailing 12-Months
Company Description
Dianthus Therapeutics
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
DNTH Stock 12 Month Forecast
Average Price Target
$58.71
▲(36.06% Upside)
Technical Analysis
Ardelyx
―
Edgewise Therapeutics
―
Janux Therapeutics Inc
―
Amylyx Pharmaceuticals Inc
―
Biohaven Ltd.
―
Ownership Overview
<0.01% Insiders
15.07% Mutual Funds
56.78% Other Institutional Investors
21.58% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---